

Contents

Preface 2010	v
Acknowledgments	v
Assistant Editors / Contributors	vi
Abbreviations.....	xvii
PART 1 The Basics.....	1
1. Introduction.....	2
The HIV epidemic	2
Transmission routes.....	4
The natural course of HIV infection	6
Disease progression stage	10
Epidemiology.....	10
Summary	11
2. HIV Testing.....	14
The basics of HIV diagnostics	14
HIV diagnostics after occupational exposure	17
What is relevant in practice?	18
Internet sources related to HIV testing.....	19
3. Pathogenesis of HIV-1 Infection	21
The structure of HIV-1.....	21
The HIV replication cycle	26
HIV and the immune system.....	33
4. Preventive HIV-1 Vaccine.....	44
Induction of neutralizing antibodies.....	44
Induction of HIV-1-specific T cells	45
Recombinant viral vectors	46
5. Acute HIV-1 Infection	48
Introduction	48
Definition and classification	48
Signs and symptoms	48
Diagnosis	49
Immunological and virological events during acute HIV-1 infection	51
Treatment	53
PART 2 Antiretroviral Therapy	57
6. ART 2010.....	58
6.1. Perspective	58
6.2. Overview of Antiretroviral Agents	62
6.3. ART 2010/2011: The Horizon and Beyond.....	107
6.4. Goals and Principles of Therapy	133

6.5. When to Start ART	149
6.6. What to Start With?	160
6.7. When to Switch?	180
6.8. How to Switch ART?.....	188
6.9. Salvage Therapy	195
6.10. When to Stop ART?	206
6.11. Monitoring	217
6.12. Prevention, compliance, costs	228
6.13. Global Access to HIV Treatment	242
7. Managing Side Effects	251
Gastrointestinal side effects	251
Hepatotoxicity.....	253
Renal problems.....	256
CNS disorders	257
Peripheral polyneuropathy	258
Changes in blood count	258
Allergic reactions	259
Lactic acidosis	261
Avascular necrosis	261
Osteopenia and Osteomalacia	262
Increased bleeding episodes	263
Specific side effects	263
8. Lipodystrophy Syndrome	268
Background	268
Clinical manifestation	268
ART, lipodystrophy syndrome and cardiovascular risk	270
Pathogenesis	271
Diagnosis	273
Therapy	274
9. Mitochondrial Toxicity of NRTIs	280
Introduction	280
Pathogenesis of mitochondrial toxicity	280
Clinical manifestations	281
Monitoring	284
Treatment & prophylaxis of mitochondrial toxicity	285
10. HIV Resistance Testing	290
Assays for resistance testing	290
Interpretation of genotypic resistance profiles	298
Summary	308
PART 3 AIDS.....	321
11. Opportunistic Infections (OIs)	322
Pneumocystis Pneumonia (PCP)	324
Cerebral toxoplasmosis	331
CMV Retinitis	336
Candidiasis	341

Tuberculosis	344
Atypical Mycobacteriosis	359
Herpes simplex	363
Herpes zoster	366
Progressive multifocal Leukoencephalopathy	368
Bacterial pneumonia	372
Cryptosporidiosis.....	375
Cryptococcosis.....	378
Salmonella septicemia.....	382
Immune reconstitution inflammatory syndrome (IRIS)	384
Wasting syndrome.....	390
Rare OIs	393
12. Kaposi's Sarcoma.....	403
13. Malignant Lymphomas.....	410
Systemic Non-Hodgkin lymphomas (NHL)	411
Primary CNS lymphoma	423
Hodgkin's disease (HD)	425
Multicentric Castleman's Disease (MCD)	428
14. Non-AIDS-defining Malignancies	433
Anal carcinoma	435
Testicular tumors	436
Bronchial carcinoma	437
PART 4 Women and Children.....	441
15. HIV and Gynaecology	442
Screening	442
HPV-associated diseases	446
16. HIV and Pregnancy	451
HIV therapy in pregnancy	451
Antiretroviral agents in pregnancy	454
Prevention of perinatal HIV infection	456
Therapy of neonates.....	459
17. HIV and Wanting to be a Parent.....	465
Introduction	465
Pre-conception counselling.....	466
The future	471
18. Antiretroviral Therapy in Children	473
Characteristics of HIV infection in childhood	473
Diagnosis of HIV infection in children	475
When to initiate ART	476
General considerations for treatment of HIV-infected children	477
Treatment strategy.....	478
Classes of antiretrovirals	479
Drug interactions.....	483

Monitoring efficacy and watching out for failure.....	483
Change of therapy.....	484
Supportive therapy and prophylaxis	484
Conclusion	485
PART 5 Special Issues	489
19. HIV and HBV/HCV Coinfections	490
HIV and HCV Coinfection	490
HIV and HBV coinfection	500
20. GBV-C Infection	507
Is GBV-C a friendly virus?	508
Proposed pathomechanisms	509
How to deal with GBV-C in clinical practice?	510
21. HIV and Renal Function	513
Nephroprotection.....	513
Clinical manifestation/diagnosis of nephropathy.....	513
Routine tests for renal impairment.....	514
HIV-associated nephropathy (HIV-AN)	515
Post-infectious glomerulonephritis	516
Principles of therapy of glomerulonephritis	517
Renal safety of antiretroviral therapy	518
Typical side effects of antiretroviral therapy	518
Dosage of antiretrovirals in renal insufficiency	520
OIs and renal insufficiency	522
22. HIV and Cardiac Diseases	526
Coronary artery (heart) disease (CHD)	526
Congestive Heart Failure	528
Pericardial effusion	529
Cardiac arrhythmias	530
Valvular heart disease / endocarditis	530
HIV-associated pulmonary arterial hypertension	531
Further cardiac manifestations	531
23. HIV and Pulmonary Diseases	535
Anamnesis	535
Pulmonary Complications	537
24. HIV and Rheumatic diseases	542
Introduction	542
Arthralgia	542
Myopathy	544
Bone complications	545
Multisystem manifestations	547
Anti-rheumatics in HIV-infected patients.....	548
25. HIV-related Thrombocytopenia	551

26. HIV and Sexually Transmitted Diseases.....	556
Epidemiology	556
Syphilis (lues)	556
Gonorrhea (the clap)	560
Chlamydia infection, lymphogranuloma venereum	562
Genital ulcers (Ulcus molle, soft chancre, chancroid)	563
Condylomata acuminata (fig warts)	564
27. HIV-associated Skin and Mucocutaneous Diseases.....	568
Introduction	568
Appendix: Frequent HIV-associated skin diseases	570
28. Sexual Dysfunction in HIV/AIDS.....	581
Introduction	581
Definitions.....	581
Etiology of sexual dysfunction in HIV/AIDS.....	582
Ongoing research	583
Diagnosis of sexual dysfunction	584
Therapy for sexual dysfunction	584
29. Traveling with HIV.....	587
Travel preparations.....	587
Antiretroviral therapy (ART)	587
General precautions	587
Vaccinations	588
Malaria prophylaxis.....	588
Entry regulations and travel insurance.....	589
Special risks.....	590
Medical problems after traveling	592
30. Vaccinations and HIV	595
Vaccinations in HIV-infected children	596
Practical approach to vaccinations	597
Details of selected vaccines	597
31. HIV-1-associated Encephalopathy and Myelopathy	608
HIV encephalopathy	608
HIV-associated myelopathy	613
32. Neuromuscular Diseases.....	616
Polyneuropathy and polyradiculopathy.....	616
Myopathy	624
33. The New (HIV-infected) Patient	626
The initial interview	626
The Laboratory	627
The examination	627
34. Post-Exposure Prophylaxis (PEP).....	629
Transmission.....	629
Transmission risk	629
Effectiveness and limitations of PEP	630

When is PEP indicated?.....	630
Potential risks of PEP.....	631
Initial interventions	631
Initiation of PEP	633
Management of PEP	634
PART 6 Drugs	637
35. Drug Profiles.....	638
3TC (lamivudine)	638
Abacavir (ABC)	638
Acyclovir.....	639
Amphotericin B	640
Atazanavir.....	641
Atovaquone	641
Atripla®	642
Azithromycin	642
AZT (zidovudine).....	643
Cidofovir	643
Clarithromycin	644
Clindamycin	645
Combivir®.....	645
Co-trimoxazole (Trimethoprim-sulfamethoxazole).....	646
d4T (stavudine).....	646
Dapsone	647
Darunavir (TMC114)	647
ddI (didanosine)	648
Delavirdine	649
Doxorubicin (liposomal).....	649
Efavirenz	650
Emtricitabine (FTC)	650
Ethambutol.....	651
Etravirine (TMC125).....	652
Fluconazole	652
Fosamprenavir	653
Foscarnet	654
Gancyclovir	654
G-CSF	655
Indinavir	655
Interferon alfa-2a/2b	656
Isoniazid (INH)	657
Itraconazole	657
Kivexa® (US: Epzicom).....	658
Lopinavir/r.....	658
Maraviroc	659
Nelfinavir	660
Nevirapine	661
Pentamidine	662
Pyrimethamine	662
Raltegravir	663
Ribavirin	663

Rifabutin	664
Rifampin	665
Ritonavir	666
Saquinavir.....	666
Sulfadiazine	667
T-20 (enfuvirtide).....	668
Tenofovir	668
Tipranavir	669
Trizivir®	670
Truvada®	670
Valgancyclovir	671
36. Drug-drug interactions.....	672
Part 1: ART + ART	673
Part 2: ART + concomitant medications.....	675
Gastrointestinal agents.....	675
Antiarrhythmic drugs.....	676
Antibiotics	677
Antidepressants	678
Antidiabetics (oral)	679
Antihistamines	679
Antihypertensive therapy.....	679
Anticonvulsants.....	679
Antimycotic agents	680
Immunosuppressants / Chemotherapeutic agents.....	681
Contraception	682
Antimalarials/ Antiprotozoals	682
Phosphodiesterase type 5 inhibitors.....	683
Statins / Lipid lowering drugs.....	683
Anti-addictive drugs	684
Antiviral drugs.....	684
Others	685
Clinical images.....	687
Index	703

Abbreviations

AIDS	Acquired Immunodeficiency Syndrome
AIN	Anal Intraepithelial Neoplasia
ART	Antiretroviral Therapy
AUC	Area under the curve
BAL	Bronchoalveolar Lavage
BGA	Blood Gas Analysis
BMI	Body Mass Index
CDC	Centers for Disease Control and Prevention
CHD	Coronary Heart Disease
CMV	Cytomegalovirus
CNS	Central Nervous System
CROI	Conference on Retroviruses and Opportunistic Infections
CT	Computed Tomography
CTL	Cytotoxic T Cells
CVC	Central Venous Catheter
DD	Differential diagnosis
DEXA	Dual Energy X-ray Absorptiometry
DNA	Deoxyribonucleic Acid
DOT	Directly Observed Therapy
EAP	Expanded Access Program
EBV	Epstein-Barr-Virus
ED	Erectile Dysfunction
ELISA	Enzyme Linked Immunosorbent Assay
ELISPOT	Enzyme Linked Immunosorbent Spot Assay
EMEA	European Medicines Agency
FDA	US Food and Drug Administration
FDC	Follicular Dendritic Cells
G-CSF	Granulocyte Colony-Stimulating Factor
GFR	Glomerular Filtration Rate
HAART	Highly Active Anti-Retroviral Therapy
HbsAG	Hepatitis B Surface Antigen
HBV	Hepatitis B Virus
HCC	Hepatocellular Carcinoma
HCV	Hepatitis C Virus
HDL	High-density Lipoprotein
HHV-8	Human Herpesvirus 8
HIV	Human Immunodeficiency Virus
HIVAN	HIV-Associated Nephropathy
HIVE	HIV-Encephalopathy
HLA	Human Leukocyte Antigen
HPV	Human Papillomavirus
HSR	Hypersensitivity Reaction
HSV	Herpes Simplex Virus
IC50	50% Inhibitory Concentration
IRIS	Immune Reconstitution Inflammatory Syndrome